<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087940</url>
  </required_header>
  <id_info>
    <org_study_id>TRYCORT 1.1</org_study_id>
    <nct_id>NCT05087940</nct_id>
  </id_info>
  <brief_title>Treatment of Resistant Hypertension: Cohort Study</brief_title>
  <acronym>TRYCORT</acronym>
  <official_title>Treatment of Resistant Hypertension: Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galenika AD Beograd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicinsko društvo za racionalnu terapiju Republike Srbije (MEDRAT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galenika AD Beograd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective observational cohort study. It will compare effectiveness&#xD;
      and safety of various add-on treatment options in regard to arterial blood pressure control&#xD;
      in adult patients with treatment resistant hypertension: an aldosterone receptor blocker&#xD;
      (e.g. spironolactone), a loop diuretic, a thiazide in large daily dose, an alpha 1 selective&#xD;
      blocker or a beta 1 selective blocker. The add-on therapy will be prescribed to the patients&#xD;
      within the scope of their routine medical care, independently from the study investigators.&#xD;
      The patients will be followed up for 6 months, with monthly visits and continuous home blood&#xD;
      pressure diary kept by the patients themselves.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective observational cohort study. It will compare effectiveness&#xD;
      and safety of various add-on treatment options in regard to arterial blood pressure control&#xD;
      in adult patients with treatment resistant hypertension: an aldosterone receptor blocker&#xD;
      (e.g. spironolactone), a loop diuretic, a thiazide in large daily dose, an alpha 1 selective&#xD;
      blocker or a beta 1 selective blocker. The add-on therapy will be prescribed to the patients&#xD;
      within the scope of their routine medical care, independently from the study investigators.&#xD;
      Both office and home blood pressure measures will be recorded at baseline and then every&#xD;
      month for 6 visits. The systolic and diastolic blood pressure targets are chosen according to&#xD;
      European guidelines for treatment of hypertension, i.e. &lt; 140/90 mmHg. Participants will have&#xD;
      contact with the study team at any time to obtain information on interim study outcomes&#xD;
      (updated medical history, completion of study questionnaires). Before, during and after the&#xD;
      study the patients will be cared for by their chosen general practitioners independently from&#xD;
      the study investigators and referred to internal medicine specialists as necessary, according&#xD;
      to diagnostic and treatment protocols currently in power at the study sites. Role of the&#xD;
      study investigators will be limited to observation and collection of data from the patients&#xD;
      themselves and from their medical files.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of normalization of arterial blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Decrease of arterial blood pressure to normal levels according to the 2018 European Society for Cardiology (ESC)/European Society for Hypertension (ESH) Guidelines (&lt;140/90 mmHg) after 1,2,3,4,5 and 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of reduction of systolic arterial blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of systolic arterial blood pressure for 10 mmHg or more after 1,2,3,4,5 and 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of reduction of diastolic arterial blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of diastolic arterial blood pressure for 5 mmHg or more after 1,2,3,4,5 and 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment withdrawal rate</measure>
    <time_frame>6 months</time_frame>
    <description>Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute value of arterial blood pressure at scheduled study visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>6 months</time_frame>
    <description>Parameters of renal function - serum level of creatinine and absolute value of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life on a scale 0 to 1</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life at a visual analogue scale</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>Resistant hypertension</arm_group_label>
    <description>The adult patients with resistant hypertension which is defined as casual blood pressure during clinical examination of more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of three or more drugs, which should include a diuretic, typically an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a calcium channel blocker (CCB). All reference blood pressures will be taken as a mean of the 2nd and 3rd measurements in physician's office during a single examination, measured at least 3 min apart. The following add-on therapy is available in Serbia, where the study is conducted: an aldosterone receptor blocker (e.g. spironolactone), a loop diuretic (e.g. furosemide), a thiazide in large daily dose, an alpha 1 selective blocker and a beta 1 selective blocker.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add-on therapy</intervention_name>
    <description>Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker</description>
    <arm_group_label>Resistant hypertension</arm_group_label>
    <other_name>An aldosterone receptor blocker, or a loop diuretic, or a thiazide in large daily dose, or an alpha 1 selective blocker, or a beta 1 selective blocker</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with resistant hypertension (casual blood pressure during clinical examination of&#xD;
        more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of three or&#xD;
        more drugs, which should include a diuretic, typically an angiotensin converting enzyme&#xD;
        (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a calcium channel blocker&#xD;
        (CCB) who meet the inclusion and exclusion criteria will be eligible for participation in&#xD;
        this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Resistant hypertension is defined as casual blood pressure during clinical examination&#xD;
             of more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of&#xD;
             three or more drugs, which should include a diuretic, typically an angiotensin&#xD;
             converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a&#xD;
             calcium channel blocker (CCB) (or beta blocker). All reference blood pressures will be&#xD;
             taken as a mean of the 2nd and 3rd measurements in physician's office during a single&#xD;
             examination, measured at least 3 min apart&#xD;
&#xD;
          3. Aged 18 years or above&#xD;
&#xD;
          4. Inadequate control of hypertension is confirmed with home blood pressure monitoring&#xD;
             (average of morning and evening measurements after 5 minutes of relaxation in sitting&#xD;
             position, for 6 days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy, anticipated pregnancy, or breastfeeding&#xD;
&#xD;
          2. Incarceration or institutionalized living which may prohibit measurement of home blood&#xD;
             pressure&#xD;
&#xD;
          3. Participation in another intervention study that may affect blood pressure&#xD;
&#xD;
          4. Patients in whom systolic blood pressure is not measurable (e.g. those with left&#xD;
             ventricular assist devices)&#xD;
&#xD;
          5. Hypotension: average systolic blood pressure &lt;100 mmHg over last 2 weeks prior to&#xD;
             screening while not taking any blood pressure medications&#xD;
&#xD;
          6. Life expectancy &lt;4 months&#xD;
&#xD;
          7. Anticipated living donor kidney transplant within 4 months&#xD;
&#xD;
          8. Patients with a systolic blood pressure value over 220 mmHg requiring immediate&#xD;
             adjustments of therapy&#xD;
&#xD;
          9. Patients with moderate to severe renal insufficiency (acute or chronic) with&#xD;
             glomerular filtration rate of less than 30 ml/min&#xD;
&#xD;
         10. Patients with active bronchospastic disorders&#xD;
&#xD;
         11. Heart failure classes III and IV&#xD;
&#xD;
         12. Severe bradycardia (heart rate below 50/min), 2nd and 3rd degree AV block&#xD;
&#xD;
         13. Patients with a history of hypersensitivity to any of the drugs under study&#xD;
&#xD;
         14. Patients already using add-on therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Branko Andjelkovic, MD</last_name>
    <role>Study Director</role>
    <affiliation>GALENIKA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Slobodan Jankovic, DSc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kragujevac, Faculty of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renata Gocic-Petrovic, MD</last_name>
    <phone>+381113071000</phone>
    <email>kontakt@galenika.rs</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Slobodan Jankovic, DSc, MD</last_name>
    <phone>+381613206392</phone>
    <email>slobnera@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sinisa Stojkovic, DSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sinisa Stojkovic, DSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radosava Cvjetan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Radosava Cvjetan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nebojsa Despotovic, DSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nebojsa Despotovic, DSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Military Academy</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nenad Ratkovic, DSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nenad Ratkovic, DSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital Center Dragisa Misovic - site 1</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slavica Radovanovic, DSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Slavica Radovanovic, DSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital Center Dragisa Misovic - site 2</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Branislav Rihor, MD</last_name>
    </contact>
    <investigator>
      <last_name>Branislav Rihor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Medical Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marija Zdravkovic, DSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marija Zdravkovic, DSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slobodan Jankovic</last_name>
    </contact>
    <investigator>
      <last_name>Slobodan Jankovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Leskovac</name>
      <address>
        <city>Leskovac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Stankovic, MD, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandar Stankovic, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomislav Kostic, MD, DSc</last_name>
    </contact>
    <investigator>
      <last_name>Tomislav Kostic, MD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiovascular Diseases of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milovan Petrovic, DSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Milovan Petrovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Subotica</name>
      <address>
        <city>Subotica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slobodan Puskar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Slobodan Puskar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Galenika AD Beograd</investigator_affiliation>
    <investigator_full_name>Slobodan Jankovic</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

